Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma PatientsCompleted
NCT03924635Phase 4Updated Jan 22, 2025
Sponsor: AstraZeneca
Airway Inflammation · Asthma
United Kingdom
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health ServicesCompleted
NCT05712096N/AUpdated Jan 21, 2025
Sponsor: AstraZeneca
SARS-CoV-2 · COVID-19
Israel
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusCompleted
NCT04515849Phase 2Updated Jan 17, 2025
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus · Chronic Kidney Diseases
Australia, Canada, Germany, Japan, New Zealand +3 more
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)Completed
NCT04716075Phase 2Updated Jan 16, 2025
Sponsor: Polish Lymphoma Research Group
Chronic Lymphocytic Leukemia · Chronic Graft-versus-host-disease · Mantle Cell Lymphoma · Adverse Event
Poland
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid TumoursCompleted
NCT03518606Phase 1, Phase 2Updated Jan 15, 2025
Sponsor: UNICANCER
Advanced Solid Tumours · Breast Cancer · Head and Neck Cancer · Cervix Cancer
France
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive Not Recruiting
NCT02299999Phase 2Updated Jan 15, 2025
Sponsor: UNICANCER
Metastatic Breast Cancer
France
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese ParticipantsCompleted
NCT06651021Phase 1Updated Jan 15, 2025
Sponsor: AstraZeneca
Healthy Volunteer
China
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompleted
NCT03509012Phase 1Updated Jan 14, 2025
Sponsor: AstraZeneca
Carcinoma, Squamous Cell of Head and Neck · Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma
United States, Japan, South Korea, Spain, Taiwan
Dapagliflozin Post Marketing Surveillance in HF and CKDCompleted
NCT05134701N/AUpdated Jan 13, 2025
Sponsor: AstraZeneca
Heart Failure · Chronic Kidney Disease
South Korea
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-OlaparibCompleted
NCT03314740Phase 2Updated Jan 10, 2025
Sponsor: Mario Negri Institute for Pharmacological Research
Ovarian Neoplasms
Italy
Real-world Study of AcalabrutinibEnrolling By Invitation
NCT06767891N/AUpdated Jan 10, 2025
Sponsor: Ruijin Hospital
MCL · CLL
China
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompleted
NCT04249362Phase 2Updated Jan 10, 2025
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, France, Italy, Poland, Russia +1 more
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With BenralizumabCompleted
NCT04159519Phase 4Updated Jan 9, 2025
Sponsor: AstraZeneca
Asthma · Severe Eosinophilic Asthma
France, Germany, Italy, United Kingdom
Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung CancerCompleted
NCT04712903Phase 3Updated Jan 7, 2025
Sponsor: AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
Spain
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin LymphomaTerminated
NCT05205161Phase 1Updated Jan 7, 2025
Sponsor: AstraZeneca
Non-Hodgkin Lymphoma
United States, Australia, France, Italy, Portugal +2 more
AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompleted
NCT02151981Phase 3Updated Jan 7, 2025
Sponsor: AstraZeneca
Anticancer Treatment
United States, Australia, Canada, China, France +13 more
Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminated
NCT04951492Phase 2Updated Jan 1, 2025
Sponsor: University of Washington
Castration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma
United States
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibNot Yet Recruiting
NCT06754761Phase 1Updated Jan 1, 2025
Sponsor: AstraZeneca
Neoplasm
United Kingdom
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.Completed
NCT04625725Phase 3Updated Dec 31, 2024
Sponsor: AstraZeneca
COVID-19
United States, Belgium, France, Spain, United Kingdom
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult ParticipantsCompleted
NCT05932641Phase 1Updated Dec 27, 2024
Sponsor: AstraZeneca
COVID-19, SARS-CoV-2
Japan
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive Not Recruiting
NCT03836261Phase 3Updated Dec 27, 2024
Sponsor: Acerta Pharma BV
Chronic Lymphocytic Leukemia
United States, Argentina, Australia, Austria, Brazil +22 more
A Study of AZD8233 in Participants With Dyslipidemia.Completed
NCT04823611Phase 1, Phase 2Updated Dec 24, 2024
Sponsor: AstraZeneca
Dyslipidemia
Japan
Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompleted
NCT05008055Phase 2Updated Dec 20, 2024
Sponsor: AstraZeneca
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
United States, Canada, Denmark, France, South Korea +2 more
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseTerminated
NCT04492722Phase 2Updated Dec 20, 2024
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Argentina, Brazil, Germany, Hungary +6 more
Durvalumab Long-Term Safety and Efficacy StudyCompleted
NCT04078152Phase 4Updated Dec 20, 2024
Sponsor: AstraZeneca
Solid Tumor
United States, Argentina, Australia, Belgium, Brazil +26 more

Previous page Next page